Alex Slack

Founding Partner at Lauxera Capital Partners

📍 United States🔄 Updated September 2026💼 7 investments📅 6 years investing🗓 Last invested Aug 2025
VC🌍 United States
7
Total investments
0
Early stage
0
Mid stage
3
Late stage
6y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Oct 2021
Streamline access, organization, and sharing of medical data to enhance the quality of care and clinical research.
Board Member
Apr 2021
LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells. Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail. Our goal is to advance science and improve human health, by providing tools that unlock the measurement of forces and interactions in biology. For the first time ever, our unapparelled solutions can assist research by directly linking structural and ‘omics analysis to functional outcomes at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.
Board Observer, Strategy & Fundraising | Accounting & Risk
Feb 2021
At Caresyntax, we are dedicated to making surgery safer and smarter. Our mission is to converge AI-powered software, devices, and clinical services to help our customers improve surgical outcomes. Our platform, an enterprise-grade surgical intelligence system, is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. The platform generates insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery. Headquartered in the US in San Francisco and internationally in Berlin, Caresyntax software is used in over 4,200 ORs globally and aids surgical teams in over 3 million procedures annually. To learn more about how we’re transforming surgical care, visit us at www.caresyntax.com.
Experience · 11 entries
All (11)
Investments (7)
Board (4)
2025
Board Member
Aug 2025
Antaros Medical was founded in 2014, with a mission to deliver innovative imaging solutions for decision-making in drug development. This mission was and still remains driven by the huge unmet need for improved medicines and tools to support their development. To meet this need, we develop and tailor imaging solutions to help pharmaceutical companies understand how their drugs work in the human body. This gives our customers support to make decisions about how to progress with their drug development projects, and helps reduce the risk and cost of getting new medicines to patients. This is really the essence of why we exist. We have grown into a global company with over 100 employees, at our headquarters and our CoreLab imaging facility in Sweden, and our subsidiary in the US. We work primarily with metabolic diseases, such as diabetes, and diseases that affect the heart, liver and kidneys, and also in the oncology field. The global clinical trials that we carry out range from small, early-stage studies to large, late-stage trials. We are proud to have worked with many of the big pharma and biotech companies and of our collaborations with academia
2023
Board Member
Jul 2023
BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality. BioLamina’s laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.
2022
Investor
Sep 2022
Verdot is a leading downstream bioprocessing technology company, founded in 1950 and headquartered in Riom, France. Verdot offers downstream purification solutions for the biopharmaceutical and food processing sectors across a range of systems, including chromatography columns, chromatography skids and tangential flow filtration systems. Our global customer base includes research and development, emerging biotech, biopharma and contract development and manufacturing organizations (CDMOs). Verdot is a specialist in the design and manufacture of fully customized, high-quality products that will enable the advancement of new therapeutic treatments along with a sustainable approach to make those biologics affordable and available to patients. For more information about Verdot, please visit www.verdot-biotechnologies.com.
2021
Investor
Oct 2021
Streamline access, organization, and sharing of medical data to enhance the quality of care and clinical research.
Board Member
Apr 2021
LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells. Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail. Our goal is to advance science and improve human health, by providing tools that unlock the measurement of forces and interactions in biology. For the first time ever, our unapparelled solutions can assist research by directly linking structural and ‘omics analysis to functional outcomes at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.
Show all 11 entries ↓
Investment activity
2020–2025 · 7 investments
2020120213202212023120251
Recent (last 2 years)Earlier